Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opioids

Young opioid abusers in the United States are not getting medicine for their addiction

The number of teenagers and young adults in the United States abusing opioid medication is growing but only around one in four are being prescribed medication to help combat their addiction, research published in JAMA Pediatrics[1] (online, 19 June 2017) shows.

Abuse of opioids often begins in adolescence or early adulthood but early intervention with buprenorphine or naltrexone can prevent relapse, overdose, premature death and lifelong harm.

The researchers used a national commercial insurance database of 9.7 million young people, aged 13–25 years, and identified 20,822 young people diagnosed with opioid use disorder (0.2 %) between 1 January 2001 and 30 June 2014. Those diagnosed had an average age of 21, and the rate of diagnosis increased nearly six-fold between 2001 and 2014.

Overall, 5,580 (26.8%) of the 20,822 young people were dispensed a medication for their addiction within six months of diagnosis, with 89.2% receiving buprenorphine and 10.8% naltrexone.

The proportion of young people prescribed a medication increased more than ten-fold between 2002 and 2009, from 3% to almost 31.8%. However, the proportion then declined to 27.5% in 2014, despite opioid use disorder diagnosis rates continuing to increase.

Analysis of the characteristics of those prescribed the drugs revealed that younger people, girls, and non-Hispanic black and Hispanic youth were less likely to receive medications.

The researchers say: “In the face of a worsening opioid crisis in the United States, strategies to expand the use of pharmacotherapy for adolescents and young adults are greatly needed, and special care is warranted to ensure equitable access for all affected youth to avoid exacerbating health disparities.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203018

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • oxycodone tablets

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.